

ResMed Denmark A/S

Kidnakken 11
4930 Maribo

CVR No. 30699246

Annual Report 2020/21

14. financial year

The Annual Report was presented and
adopted at the Annual General Meeting of
the Company on 15 November 2021

DocuSigned by:

Jussi Vuorela

4DD3E4C04A53440...

Chairman

ResMed Denmark A/S

Contents

Management's Statement	3
Independent Auditors' Report	4
Company Information	6
Management's Review	7
Accounting Policies	8
Income Statement	12
Balance Sheet	13
Statement of changes in Equity	15
Notes	16

ResMed Denmark A/S

Management's Statement

Today, Management has considered and adopted the Annual Report of ResMed Denmark A/S for the financial year 1 July 2020 - 30 June 2021.

The Annual Report is presented in accordance with the Danish Financial Statements Act.

In our opinion, the Financial Statements give a true and fair view of the assets, liabilities and financial position of the Company at 30 June 2021 and of the results of the Company's operations for the financial year 1 July 2020 - 30 June 2021.

In our opinion, the Management's Review includes a true and fair account of the matters addressed in the review.

We recommend that the Annual Report be adopted at the Annual General Meeting.

Maribo, 15 November 2021

Executive Board

DocuSigned by:
Malene Petersen
910A693E62AA493
Malene Bruun Petersen
Manager

Supervisory Board

DocuSigned by:
Jussi Vuorela
4DD354C01A534401a
Jussi Antero Vuorela
Member

DocuSigned by:
David Pendarvis
58A9E9F064AF427
David Brian Pendarvis
Member

DocuSigned by:
Nigel Robinson
C736E00FF864CB
Nigel Wayne Robinson
Member

ResMed Denmark A/S

Independent Auditors' Report**To the shareholders of ResMed Denmark A/S****Opinion**

We have audited the financial statements of ResMed Denmark A/S for the financial year 1 July 2020 - 30 June 2021, which comprise an income statement, balance sheet, statement of changes in equity and notes. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Company's financial position at 30 June 2021 and of the results of its operations for the financial year 1 July 2020 - 30 June 2021 in accordance with the Danish Financial Statements Act.

Basis of opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibility under those standards and requirements are further described in our auditors' report under "Auditors' responsibility for the audit of the financial statements". As required by the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and additional requirements applicable in Denmark, we are independent of the Company, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's responsibility for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management considers necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern; disclosing, as applicable, matters related to going concern; and using the going concern basis of accounting in preparing the financial statements unless Management either intends to either liquidate the Company or suspend operations, or has no realistic alternative but to do so.

The auditor's responsibility for the audit of the financial statements

Our responsibility is to obtain reasonable assurance as to whether the financial statements are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is no guarantee that an audit conducted in accordance with ISAs and additional requirements applicable in Denmark will always detect material misstatements. Misstatements can arise from fraud or error and can be considered material if it would be reasonable to expect that these - either individually or collectively - could influence the economic decisions taken by the users of financial statements on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and additional requirements applicable in Denmark, we exercise professional judgement and maintain an attitude of professional skepticism throughout the audit. We also:

- * Identify and assess the risk of material misstatements in the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for a material misstatement resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or override of internal control.
- * Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- * Evaluate whether the accounting policies used are appropriate and whether the accounting estimates and the related disclosures made by Management are reasonable.
- * Conclude on whether Management's use of the going concern basis of accounting in preparing the financial

ResMed Denmark A/S

Independent Auditors' Report

statements is appropriate and, based on the audit evidence obtained, conclude on whether a material uncertainty exists relating to events or conditions, which could cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may imply that the Company can no longer remain a going concern.

- * Evaluate the overall presentation, structure and contents of the financial statements, including note disclosures, and whether the financial statements reflect the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control which we identify during our audit.

Statement on Management's Review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of opinion providing assurance regarding the Management's review.

Our responsibility in connection with our audit of the financial statements is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or with the knowledge we have gained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review meets the disclosure requirements in the Danish Financial Statements Act.


Based on our procedures, we are of the opinion that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements in the Danish Financial Statements Act. In our opinion, the Management's review is not materially misstated.

Maribo, 15 November 2021

aage maagensen

statsautoriseret revisionsaktieselskab

CVR-no. 12901038

DocuSigned by:

2759F84667D6448...

Christina Wibholm

State Authorised Public Accountant

mne35784

ResMed Denmark A/S

Company details

Company	ResMed Denmark A/S Kidnakken 11 4930 Maribo
Telephone	54 75 75 45
Telefax	54 75 95 45
email	info@resmed.dk
Website	www.resmed.dk
CVR No.	30699246
Date of formation	27 June 2007
Supervisory Board	Jussi Antero Vuorela David Brian Pendarvis Nigel Wayne Robinson
Executive Board	Malene Brun Petersen, Manager
Auditors	aage maagensen statsautoriseret revisionsaktieselskab C.E. Christiansens Vej 56 4930 Maribo CVR-no.: 12901038
Bank	Danske Bank

ResMed Denmark A/S

Management's Review

The Company's principal activities

The Company's principal activities consist in import and sale of medical equipment.

Development in activities and the financial situation

The Company's Income Statement of the financial year 1 July 2020 - 30 June 2021 shows a result of DKK 3.404.433 and the Balance Sheet at 30 June 2021 a balance sheet total of DKK 36.085.027 and an equity of DKK 18.848.625.

Material changes in the Company's operations and financial matters

After the end of the financial year, no events has occurred which may charge the financial position of the entity substantially.

ResMed Denmark A/S

Accounting Policies**Reporting Class**

The Annual Report has been presented in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B, with the adoption of individual rules from class C.

The accounting policies applied remain unchanged from last year.

Reporting currency

The Annual Report is presented in Danish kroner.

Translation policies

Transactions in foreign currencies are translated into DKK at the exchange rate prevailing at the date of transaction. Monetary assets and liabilities in foreign currencies are translated into DKK based on the exchange rates prevailing at the balance sheet day. Realised and unrealised foreign exchange gains and losses are included in the Income Statement under Financial Income and Expenses.

General Information**Basis of recognition and measurement**

The financial statement have been prepared under the historical cost principle.

Income is recognised in the Income Statement as it is earned, including value adjustments of financial assets and liabilities that are measured at fair value or amortised cost. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the Income Statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the Income Statement.

Assets are recognised in the Balance Sheet when it is probable that future economic benefits attributable to the asset will accrue to the Company, and the value of the asset can be measured reliably.

Liabilities are recognised in the Balance Sheet when it is probable that future economic benefits attributable to the asset will flow out of the Company, and the value of the liability can be measured reliably.

At initial recognition, assets and liabilities are measured at cost. Subsequently, assets and liabilities are measured as described for each item below.

Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the term. Amortised cost is calculated as original cost less repayments and with the addition/deduction of the accumulated amortisation of the difference between the cost and the nominal amount. This way, exchange losses and gains are allocated over the term.

In connection with recognition and measurement, consideration is given to predictable losses and risks occurring prior to the presentation of the Annual Report, i.e. losses and risks which prove or disprove matters which exist at the balance sheet date.

ResMed Denmark A/S

Accounting Policies**Income Statement****Gross profit/loss**

The Company has decided to aggregate certain items of the Income Statement in accordance with the provisions of Section 32 of the Danish Financial Statements Act.

Gross profit is a combination of the items of revenue, change in inventories of finished goods, work in progress and goods for resale, other operation income, cost of raw and consumables and other external expenses.

Revenue

Income from the sale of goods for resale and finished goods is recognised in the income statement if the goods have been delivered and the risk has passed to the buyer before year-end, if it is possible to calculate the income reliably. The revenue is exclusive of VAT and net of sales discounts.

Other external expenses

Other external costs include costs for distribution, sales, advertising, administration, premises. Loss of debtors, operating leasing costs etc.

Staff expenses

Staff expenses comprise wages, salaries and other pay-related costs, such as sickness benefits for enterprise employees less wage/salary reimbursement, pensions and social security costs.

Amortisation and impairment of tangible and intangible assets

Amortisation and impairment of intangible and tangible assets has been performed based on a continuing assessment of the useful life of the assets in the Company. Non-current assets are amortised on a straight line basis, based on cost, on the basis of the following assessment of useful life and residual values:

	Useful life	Residual value
Other fixtures and fittings, tools and equipment	3-10 years	0%
Leasehold improvements	5 years	0%

Profit or loss resulting from the sale of intangible or tangible assets is determined as the difference between the selling price less selling costs and the carrying amount at the date of sale, and is recognised in the Income Statement under other operating income or expenses.

Financial income and expenses

Financial income and expenses are recognised in the Income Statement based on the amounts that concern the financial year. Financial income and expenses include interest revenue and expenses, financial expenses of finance leases, realised and unrealised capital gains and losses regarding securities, accounts payable and transactions in foreign currencies, repayment on mortgage loans, and surcharges and allowances under the tax prepayment scheme.

Tax on net profit for the year

Tax on net profit/loss for the year comprises current tax on expected taxable income of the year and the year's adjustment of deferred tax less the part of the tax of the year that relates to changes in equity. Current and deferred tax regarding changes in equity is recognised directly in equity.

ResMed Denmark A/S

Accounting Policies**Balance Sheet****Property, plant and equipment**

Tangible assets are measured at cost on initial recognition and subsequently at cost less accumulated depreciation and impairment losses.

The depreciable amount is calculated taking into consideration the residual value of the asset at the end of its useful life, reduced by impairment losses, if any. The depreciation period and the residual value are determined at the date of acquisition. If the residual value exceeds the carrying amount of the asset, depreciation is discontinued.

In case of changes in depreciation period or residual value, the effect of a change in depreciation period is recognised prospectively in accounting estimates.

Cost includes the purchase price and expenses directly related to the acquisition until the time when the asset is ready for use. The cost of self-constructed assets includes costs for materials, components, subcontractors, direct payroll costs and indirect production costs.

The cost of composite asset is disaggregated into components, which are separately depreciated if the useful lives of the individual components differ.

Other long-term receivables

Deposits are measured at cost.

Inventories

Inventories are measured at cost on the basis of the FIFO principle. Where the net realisable value is lower than cost, the inventories are written down to this lower value.

Merchandise are measured at cost comprising purchase price plus delivery costs.

Receivables

Receivables are measured at amortised cost which usually corresponds to the nominal value. The value is reduced by write-downs for expected bad debts.

Impairment of accounts receivables past due is established on individual assessment of receivables.

Accrued income, assets

Accrued income recognised in assets comprises prepaid costs regarding subsequent financial years.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand as well as short-term securities with a term of less than three months which can be converted directly into cash at bank and in hand and involve only an insignificant risk of value changes.

Equity

Equity comprises the working capital and a number of equity items that may be statutory or stipulated in the articles of association.

Proposed dividend for the year is recognised as a separate item in equity.

Provisions

Provisions comprise expected costs of warranty commitments, loss on work in progress, restructuring, etc. Provisions are recognised when the Company has a legal or actual obligation as a result of a past event, and it is likely that settlement will result in the company spending financial resources.

Provisions that measured at value in use.

ResMed Denmark A/S

Accounting Policies**Current tax liabilities**

Current tax liabilities and current tax receivables are recognised in the Balance Sheet as calculated tax on the expected taxable income for the year, adjusted for tax on taxable income for previous years as well as for tax prepaid.

Liabilities

Financial liabilities are recognised initially at the proceeds received net of transaction expenses incurred. In subsequent periods, financial liabilities are measured at amortised cost, corresponding to the capitalised value using the effective interest method, so that the difference between the proceeds and the nominal value is recognised in the Income Statement over the life of the financial instrument.

Mortgage debt is accordingly measured at amortised cost, corresponding to the outstanding balance in case of cash loans. In case of bond loans, amortised cost corresponds to the outstanding balance determined as the underlying cash value of the loans at the time of borrowing adjusted for amortisation of capital losses on the loans over the repayment period.

Other liabilities, comprising deposits, trade payables and other accounts payable, are measured at amortised cost, which usually corresponds to the nominal value.

Contingent assets and liabilities

Contingent assets and liabilities are not recognised in the Balance Sheet but appear only in the notes.

ResMed Denmark A/S**Income Statement**

	Note	2020/21 kr.	2019/20 kr.
Gross profit		15.491.711	13.913.907
Employee benefits expense	1	-11.010.913	-10.454.393
Depreciation, amortisation expense and impairment losses of property, plant and equipment and intangible assets recognised in profit or loss		-39.684	-63.423
Profit from ordinary operating activities		4.441.114	3.396.091
Other finance income		0	14
Finance expenses		-67.982	-37.740
Profit from ordinary activities before tax		4.373.132	3.358.365
Tax expense on ordinary activities	2	-968.699	-741.262
Profit		3.404.433	2.617.103
 Proposed distribution of results			
Retained earnings		3.404.433	2.617.103
Distribution of profit		3.404.433	2.617.103

ResMed Denmark A/S

Balance Sheet as of 30 June

	Note	2021 kr.	2020 kr.
Assets			
Fixtures, fittings, tools and equipment		34.168	73.852
Property, plant and equipment		34.168	73.852
Other long-term receivables		1.245.661	1.094.364
Investments		1.245.661	1.094.364
Fixed assets		1.279.829	1.168.216
Manufactured goods and goods for resale		5.917.245	3.982.716
Inventories		5.917.245	3.982.716
Short-term trade receivables		6.858.523	8.637.004
Short-term receivables from group enterprises		5.744.405	2.758.979
Current deferred tax		274.841	266.483
Receivables		12.877.769	11.662.466
Cash and cash equivalents		16.010.184	7.735.010
Current assets		34.805.198	23.380.192
Assets		36.085.027	24.548.408

ResMed Denmark A/S**Balance Sheet as of 30 June**

	Note	2021 kr.	2020 kr.
Liabilities and equity			
Contributed capital		556.000	556.000
Retained earnings		18.292.625	14.888.193
Equity		18.848.625	15.444.193
Other provisions	3	1.024.424	939.781
Provisions		1.024.424	939.781
Other payables		1.044.186	853.071
Long-term liabilities other than provisions	4	1.044.186	853.071
Trade payables		869.358	450.175
Payables to group enterprises		10.427.586	4.508.875
Tax payables		601.699	502.513
Other payables		3.269.149	1.849.800
Short-term liabilities other than provisions		15.167.792	7.311.363
Liabilities other than provisions within the business		16.211.978	8.164.434
Liabilities and equity		36.085.027	24.548.408
Contingent liabilities	5		
Collaterals and assets pledges as security	6		

ResMed Denmark A/S**Statement of changes in Equity**

	Contributed capital	Retained earnings	Proposed dividend recognised in equity	Total
Equity 1 July 2020	556.000	14.888.192	0	15.444.192
Profit (loss)	0	3.404.433	0	3.404.433
Equity 30 June 2021	556.000	18.292.625	0	18.848.625

ResMed Denmark A/S**Notes****1. Employee benefits expense**

	2020/21	2019/20
Wages and salaries	9.573.660	9.048.890
Social security contributions	1.437.253	1.405.503
	11.010.913	10.454.393
Average number of employees	16	16

2. Tax expense

Tax on profit for the year	977.056	768.871
Changes in derred tax	-8.357	-27.609
	968.699	741.262

3. Other provisions

Extended warranty	1.024.424	939.781
Balance at the end of the year	1.024.424	939.781

4. Long-term liabilities

	Due after 1 year	Due within 1 year	Due after 5 years
Other payables	1.044.186	0	0
	1.044.186	0	0

5. Contingent liabilities

There are rent-contracts with a total liability amount of tDKK 1.553 and leasing- and rental liability of tDKK 545.

6. Collaterals and securities

No securities or mortgages exist at the balance sheet date.